

What is claimed is:

1. A medicament for prophylactic and/or therapeutic treatment of a vascular disease, which comprises as an active ingredient a substance selected from the group consisting of a retinoid and an agent for controlling an action of a retinoid, wherein said substance has substantially no antiproliferative action on vascular endothelial cells, but substantially has antiproliferative action on vascular smooth muscle cells.

2. The medicament according to claim 1, wherein the vascular disease is selected from the group consisting of arteriosclerosis, a cerebrovascular disorder, and a vascular disease due to intravascular physical injury.

3. The medicament according to claim 2, wherein the vascular disease due to intravascular physical injury is vascular restenosis and/or reocclusion after percutaneous transluminal coronary angioplasty using an intravascular stent.

4. The medicament according to claim 3, which is contained in an intravascular stent or a balloon catheter in a form that enables a sustained release of said medicament.

5. The medicament according to any one of claims 1 to 4, wherein the substance as the active ingredient is 4-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]carbamoyl]benzoic acid or a salt thereof, or 4-[[[3,5-bis(trimethylsilyl)phenyl]carbonyl]amino]benzoic acid or a salt thereof.

6. A medicament for suppressing granulation due to intravascular physical injury, which comprises a substance selected from the group consisting of a retinoid and an agent for controlling an action of a retinoid as an active ingredient.

7. The medicament according to claim 6, wherein the substance has substantial antiproliferative action on neointima of an injured blood vessel.

8. A medicament for suppressing proliferation of neointima due to intravascular physical injury, which comprises a substance selected from the group consisting of a retinoid and an agent for controlling an action of a retinoid as an active ingredient.

9. A medicament for prophylactic and/or therapeutic treatment of hypercardia, which comprises a substance selected from the group consisting of a retinoid and an agent for controlling an action of a retinoid as an active ingredient.

10. A medicament for suppressing fibrosis in hypercardia, which comprises a substance selected from the group consisting of a retinoid and an agent for controlling an action of a retinoid as an active ingredient.

11. The medicament according to any one of claims 6 to 10, wherein the substance as the active ingredient is 4-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]carbamoyl]benzoic acid or a salt thereof, or 4-[[[3,5-bis(trimethylsilyl)-phenyl]carbonyl]amino]benzoic acid or a salt thereof.

12. An intravascular stent or an intravascular balloon catheter, which contains the medicament according to any one of claims 6 to 8 in a form that enables a sustained release of said medicament.